{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:05:47Z","timestamp":1791572747503,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009429","name":"Israel National Road Safety Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["1 F32 HS028749-01"],"award-info":[{"award-number":["1 F32 HS028749-01"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.japh.2022.10.004","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T07:20:19Z","timestamp":1665732019000},"page":"336-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Community pharmacist-provided opioid intervention frequencies and barriers"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7185-4949","authenticated-orcid":false,"given":"Molly A.","family":"Nichols","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen L.","family":"Kepley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8358-961X","authenticated-orcid":false,"given":"Kylee S.","family":"Rosko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3713-5510","authenticated-orcid":false,"given":"Karen Suchanek","family":"Hudmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey M.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1482-8020","authenticated-orcid":false,"given":"Margie E.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.japh.2022.10.004_bib4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ajhp\/zxy089","article-title":"The opioid crisis: origins, trends, policies, and the roles of pharmacists","volume":"76","author":"Chisholm-Burns","year":"2019","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.japh.2022.10.004_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13722-019-0158-0","article-title":"Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders","volume":"14","author":"Bach","year":"2019","journal-title":"Addict Sci Clin Pract"},{"issue":"2","key":"10.1016\/j.japh.2022.10.004_bib6","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/jac5.1171","article-title":"Pharmacists and the opioid crisis: a narrative review of pharmacists\u2019 practice roles","volume":"3","author":"Bratberg","year":"2019","journal-title":"J\u00a0Am Coll Clin Pharm"},{"issue":"6","key":"10.1016\/j.japh.2022.10.004_bib7","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/add.15314","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA","volume":"116","author":"Hill","year":"2021","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.japh.2022.10.004_bib8","first-page":"272","article-title":"Naloxone availability and pharmacy staff knowledge of Standing order for naloxone in pennsylvania pharmacies","volume":"13","author":"Graves","year":"2019","journal-title":"J\u00a0Addict Med"},{"issue":"6","key":"10.1016\/j.japh.2022.10.004_bib9","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/j.amepre.2021.05.042","article-title":"Trends in state-level pharmacy-based naloxone dispensing rates, 2012-2019","volume":"61","author":"Guy","year":"2021","journal-title":"Am J Prev Med"},{"issue":"1","key":"10.1016\/j.japh.2022.10.004_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1331\/JAPhA.2015.14148","article-title":"Nonprescription syringe sales: a missed opportunity for HIV prevention in California","volume":"55","author":"Pollini","year":"2015","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"1","key":"10.1016\/j.japh.2022.10.004_bib11","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.japh.2019.06.016","article-title":"Pharmacist roles, training, and perceived barriers in naloxone dispensing: a systematic review","volume":"60","author":"Thakur","year":"2020","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"4","key":"10.1016\/j.japh.2022.10.004_bib12","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/08897077.2019.1616349","article-title":"Pharmacists\u2019 attitudes toward dispensing naloxone and medications for opioid use disorder: a scoping review of the literature","volume":"40","author":"Muzyk","year":"2019","journal-title":"Subst Abus"},{"issue":"1","key":"10.1016\/j.japh.2022.10.004_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/pharmacy7010011","article-title":"Readiness of pharmacists based in Utah about pain management and opioid dispensing","volume":"7","author":"Balough","year":"2019","journal-title":"Pharmacy (Basel)"},{"issue":"2S","key":"10.1016\/j.japh.2022.10.004_bib14","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.japh.2017.01.013","article-title":"Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states","volume":"57","author":"Green","year":"2017","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"2","key":"10.1016\/j.japh.2022.10.004_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/jac5.1556","article-title":"Pharmacists and opioid use disorder care during COVID-19: call for action","volume":"5","author":"Mohammad","year":"2022","journal-title":"J\u00a0Am Coll Clin Pharm"},{"issue":"3","key":"10.1016\/j.japh.2022.10.004_bib16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/08897077.2017.1391924","article-title":"Barriers and facilitators to dispensing of intranasal naloxone by pharmacists","volume":"39","author":"Bakhireva","year":"2018","journal-title":"Subst Abus"},{"issue":"14","key":"10.1016\/j.japh.2022.10.004_bib17","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1080\/10826084.2021.1968434","article-title":"Pharmacist views regarding the prescription opioid epidemic","volume":"56","author":"Rao","year":"2021","journal-title":"Subst Use Misuse"},{"issue":"2-3","key":"10.1016\/j.japh.2022.10.004_bib18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.healthpol.2011.10.012","article-title":"Health workers at the core of the health system: framework and research issues","volume":"105","author":"Anand","year":"2012","journal-title":"Health Policy"},{"issue":"6","key":"10.1016\/j.japh.2022.10.004_bib24","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.japh.2020.06.008","article-title":"Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: a descriptive analysis","volume":"60","author":"Salwan","year":"2020","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"1","key":"10.1016\/j.japh.2022.10.004_bib25","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.18549\/PharmPract.2020.1.1682","article-title":"Differences between pharmacists\u2019 perception of counseling and practice in the era of prescription drug misuse","volume":"18","author":"Thornton","year":"2020","journal-title":"Pharm Pract (Granada)"},{"issue":"5","key":"10.1016\/j.japh.2022.10.004_bib26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/0897190010379710","article-title":"Pharmacist\u2019s role in dispensing opioids for acute and chronic pain","volume":"25","author":"Marlowe","year":"2012","journal-title":"J\u00a0Pharm Pract"},{"issue":"6","key":"10.1016\/j.japh.2022.10.004_bib27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.japh.2019.06.019","article-title":"Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction","volume":"59","author":"Hill","year":"2019","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"2","key":"10.1016\/j.japh.2022.10.004_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jphs.12013","article-title":"Pharmacists' knowledge, attitudes and beliefs regarding screening and brief intervention for prescription opioid abuse: a survey of Utah and Texas pharmacists","volume":"4","author":"Cochran","year":"2013","journal-title":"J\u00a0Pharm Health Serv Res"},{"issue":"2","key":"10.1016\/j.japh.2022.10.004_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.sapharm.2015.05.001","article-title":"Developing a framework of care for opioid medication misuse in community pharmacy","volume":"12","author":"Cochran","year":"2016","journal-title":"Res Social Adm Pharm"},{"issue":"1","key":"10.1016\/j.japh.2022.10.004_bib31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.japh.2021.08.018","article-title":"Development and validation of patient-community pharmacist encounter toolkit regarding substance misuse: Delphi procedure","volume":"62","author":"Fatani","year":"2022","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"5","key":"10.1016\/j.japh.2022.10.004_bib32","first-page":"403","article-title":"Screening, brief intervention, and referral to treatment in a retail pharmacy setting: the Pharmacist's role in identifying and addressing risk of substance Use disorder","volume":"13","author":"Shonesy","year":"2019","journal-title":"J\u00a0Addict Med"},{"issue":"3","key":"10.1016\/j.japh.2022.10.004_bib33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/00048670802653349","article-title":"Desire for social distance from people with mental disorders","volume":"43","author":"Jorm","year":"2009","journal-title":"Aust N Z J Psychiatry"},{"issue":"4","key":"10.1016\/j.japh.2022.10.004_bib34","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/08897077.2021.1900988","article-title":"Pharmacists' stigma toward patients engaged in opioid misuse: when \u201csocial distance\u201d does not mean disease prevention","volume":"42","author":"Werremeyer","year":"2021","journal-title":"Subst Abus"},{"issue":"1-2","key":"10.1016\/j.japh.2022.10.004_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","article-title":"Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review","volume":"131","author":"Van Boekel","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2022.10.004_bib36","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.socscimed.2019.05.027","article-title":"Intervention stigma: how medication-assisted treatment marginalizes patients and providers","volume":"232","author":"Madden","year":"2019","journal-title":"Soc Sci Med"},{"issue":"3S","key":"10.1016\/j.japh.2022.10.004_bib37","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.japh.2020.01.001","article-title":"Indiana community pharmacist preceptors' knowledge and perceptions of medication-assisted treatment","volume":"60","author":"Davenport","year":"2020","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"14","key":"10.1016\/j.japh.2022.10.004_bib38","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","article-title":"Intervention stigma toward medications for opioid use disorder: a systematic review","volume":"56","author":"Madden","year":"2021","journal-title":"Subst Use Misuse"},{"issue":"4","key":"10.1016\/j.japh.2022.10.004_bib39","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/jac5.1147","article-title":"Unrealized potential and unrecognized value: community-based pharmacy practice is reinventing itself \u2013 join the movement","volume":"2","author":"Somma McGivney","year":"2019","journal-title":"J\u00a0Am Coll Clin Pharm"},{"key":"10.1016\/j.japh.2022.10.004_bib41","author":"Gabler"},{"key":"10.1016\/j.japh.2022.10.004_bib42","author":"Arya"},{"key":"10.1016\/j.japh.2022.10.004_bib44","article-title":"Opioid use disorder content in US-based Doctor of Pharmacy Programs","author":"Nichols","year":"2022","journal-title":"Am J Pharm Educ"},{"issue":"7","key":"10.1016\/j.japh.2022.10.004_bib45","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.5688\/ajpe8175925","article-title":"Curriculum in psychiatry and neurology for pharmacy programs","volume":"81","author":"Dopheide","year":"2017","journal-title":"Am J Pharm Educ"},{"issue":"1","key":"10.1016\/j.japh.2022.10.004_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.9740\/mhc.2018.01.014","article-title":"Surveys of substance use disorders education in US pharmacy programs","volume":"8","author":"Thomas","year":"2018","journal-title":"Ment Health Clin"},{"issue":"1","key":"10.1016\/j.japh.2022.10.004_bib47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0002-9459(24)03170-X","article-title":"Mental health and psychiatric pharmacy instruction in US colleges and schools of pharmacy","volume":"71","author":"Cates","year":"2007","journal-title":"Am J Pharm Educ"},{"issue":"4","key":"10.1016\/j.japh.2022.10.004_bib48","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/0897190014522064","article-title":"Pharmacists who screen and discuss opioid misuse with patients: future directions for research and practice","volume":"28","author":"Cochran","year":"2015","journal-title":"J\u00a0Pharm Pract"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122003302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122003302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:51:00Z","timestamp":1761544260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319122003302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1544319122003302"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2022.10.004","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Community pharmacist-provided opioid intervention frequencies and barriers","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2022.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}